AbCellera Biologics Inc. (ABCL) Spending and interest coverage
- R&D / revenue · 12 months: Value 298.88%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 77.22%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 298.88% | Research and development expense / revenue. Period ending 2026-06-30. $197.77M ÷ $66.17M × 100 ≈ 298.88% |
| Stock-based compensation / revenue · 12 months | 77.22% | Share-based compensation / revenue. Period ending 2026-06-30. $51.10M ÷ $66.17M × 100 ≈ 77.22% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 197.77M USD | Research and Development Expense |
| Revenue | 66.17M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 51.10M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -225.16M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $197.77M | $66.17M | $51.10M | $-225.16M | (m) | 298.88% | 77.22% | (m) | (m) |
| 2026-03-31 | $191.00M | $79.21M | $53.02M | $-211.96M | (m) | 241.13% | 66.94% | (m) | (m) |
| 2025-12-31 | $186.83M | $75.13M | $55.79M | $-217.10M | (m) | 248.68% | 74.26% | (m) | (m) |
| 2025-09-30 | $182.81M | $35.33M | $58.11M | $-261.28M | (m) | 517.51% | 164.51% | (m) | (m) |
| 2025-06-30 | $168.76M | $32.88M | $61.38M | $-278.66M | (m) | 513.31% | 186.71% | (m) | (m) |
| 2025-03-31 | $170.47M | $23.11M | $64.96M | $-322.53M | (m) | 737.51% | 281.03% | (m) | (m) |
| 2024-12-31 | $167.26M | $28.83M | $67.58M | $-314.77M | (m) | 580.10% | 234.39% | (m) | (m) |
| 2024-09-30 | $169.81M | $32.96M | $68.80M | $-308.06M | (m) | 515.15% | 208.73% | (m) | (m) |
| 2024-06-30 | $166.75M | $33.05M | $67.50M | $-269.29M | (m) | 504.48% | 204.21% | (m) | (m) |
| 2024-03-31 | $162.30M | $35.79M | $66.12M | $-227.23M | (m) | 453.51% | 184.75% | (m) | (m) |
| 2023-12-31 | $175.66M | $38.02M | $64.18M | $-237.21M | (m) | 461.95% | 168.79% | (m) | (m) |
| 2023-09-30 | $155.28M | $50.39M | $61.06M | $-208.93M | (m) | 308.15% | 121.17% | (m) | (m) |
| 2023-06-30 | $143.95M | $145.18M | $56.95M | $-116.31M | (m) | 99.15% | 39.23% | (m) | (m) |
| 2023-03-31 | $134.16M | $181.03M | $52.66M | $-73.31M | (m) | 74.11% | 29.09% | (m) | (m) |
| 2022-12-31 | $107.88M | $485.42M | $49.48M | $216.51M | (m) | 22.22% | 10.19% | (m) | (m) |
| 2022-09-30 | $96.84M | $603.21M | $45.20M | $335.84M | (m) | 16.05% | 7.49% | (m) | (m) |
| 2022-06-30 | $87.71M | $507.32M | $41.15M | $269.99M | (m) | 17.29% | 8.11% | (m) | (m) |
| 2022-03-31 | $76.08M | $489.04M | $37.51M | $271.29M | (m) | 15.56% | 7.67% | (m) | (m) |
| 2021-12-31 | $62.06M | $375.20M | $30.65M | $204.41M | (m) | 16.54% | 8.17% | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $29.39M | $233.16M | $8.40M | $156.03M | (m) | 12.61% | 3.60% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $10.11M | $11.61M | $890.00K | $-4.12M | (m) | 87.09% | 7.66% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |